Intellia Therapeutics, Inc. (NTLA)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3), so the fundamental gate blocks any bullish entry regardless of the chart; separately, no entry type qualifies — a pullback/oversold limit is countertrend (price 10.55 < SMA50 11.98 with MACD -0.22 < 0, and below a declining SMA200 12.98 with SMA50 < SMA200 and no momentum reclaim), and no breakout stop qualifies (price is below every short-term average with MACD expanding negative, so a stop above the nearest settled swing high 12.15 would be a chase into overhead supply).
Company overview
Intellia Therapeutics, Inc. is a biotechnology company focused on developing therapeutic treatments using genome editing. It has several in vivo and ex vivo programs targeting conditions like transthyretin amyloidosis and hereditary angioedema, leveraging CRISPR/Cas9 technology. The company collaborates with partners like Novartis and Regeneron to advance its pipeline.
Fundamental
weakIntellia's fundamentals are weak, with no product revenue, significant net losses, and a high dilution risk.
Pre-revenue CRISPR gene-editing company where strong liquidity ($614.8M cash and securities at 30-Sep-2026, runway guided into 2028, no going concern, no funded debt until a $75M secured draw in September 2026) is offset by a $330.4M nine-month net loss, revenue down 33% year to date, an 11.1% senior secured facility pledging all assets including IP, and roughly 21% share-count growth in nine months with $368.5M of ATM capacity remaining. Operating cash burn is improving while the income statement is not; conventional multiples and both DCF models are non-meaningful for a company with no product revenue, and the equity is effectively a binary bet on the 10-Mar-2027 lonvo-z regulatory decision, with nex-z safety, patent litigation and an open dilution spigot as the main downside amplifiers.
Sentiment
fairSentiment is mixed with both positive clinical data and negative financial results impacting the outlook.
A genuinely mixed setup: the tape is working through a Q3 2026 print it sold (EPS -$0.91 vs -$0.82; revenue $7.2M vs $9.7M FactSet; two aggregator items scored -0.4 and Yahoo ran 'Q3 Loss Wider Than Expected, Stock Down') against three announced bullish legs — same-day positive lonvo-z ACAAI 2026 data, completed MAGNITUDE-2 Phase 3 enrollment, and a regulator-confirmed lonvo-z PDUFA on 2027-03-10. Media sentiment shows a determinate but modest cooling (baseline polarity ~ +0.23 on n=3 to scoring ~ -0.05 on n=9) rather than a negative flip; retail is indeterminate after a Reddit 403 block; no severe red flag fired. Because the actionable window holds both bullish and bearish catalysts, the moderate conflicting-catalysts flag fires and a moderate red-flag cap applies.
Technical
very weakThe stock is in a downtrend, trading below key moving averages with no bullish confirmation.
Bearish/broken structure with no bullish confirmation anywhere in the stack: price 10.55 sits below the SMA20 (11.75), SMA50 (11.98) and SMA200 (12.98) and below every short-lag average (EMA9 11.45, EMA21 11.72, WMA9 11.35, WMA21 11.70, DEMA14 11.31, TEMA14 11.11) as well as the day's VWAP 10.7675; MACD is negative (-0.22) below its signal (-0.10) with the histogram expanding negative (-0.12 vs +0.05 on 2026-11-04); RSI14 is 40.92 and falling; Williams %R is -97.41; ADX14 is 10.76 (weak, direction-agnostic strength reading). The stock closed 0.06 above the session low after a -7.5% session, the latest in a run of lower highs from 13.16 (10-30) to 11.06 (11-12). Fundamentals independently block the trade (fundamentalScore 2 < 3), but the chart itself earns a 1.
You’re looking at 2026-11-12 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

